Literature DB >> 22069047

Hyperemesis and a high water bill.

S Fleig1, R Brunkhorst.   

Abstract

A male patient aged 28 years was admitted with hyperemesis that did not cease in spite of different therapeutic approaches and had persisted for several days. A wide range of differential diagnoses was excluded and all tests remained without pathological findings. He reported regular cannabis use and showed abnormal bathing behavior taking hot showers several times a day for more than one hour each, which was the only measure to ease his nausea; on the basis of these clinical findings, the diagnosis of cannabinoid hyperemesis syndrome was made. After detoxification, he remained free of symptoms. Cannabinoid hyperemesis syndrome was first described in 2004 in Australia and is an underrecognized cause of hyperemesis and abnormal bathing behavior. To the best of our knowledge, this is the first reported case in Germany. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2011        PMID: 22069047     DOI: 10.1055/s-0029-1246107

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  4 in total

Review 1.  Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

Authors:  Cecilia J Sorensen; Kristen DeSanto; Laura Borgelt; Kristina T Phillips; Andrew A Monte
Journal:  J Med Toxicol       Date:  2016-12-20

2.  Cannabinoid hyperemesis syndrome.

Authors:  Jai D Parekh; Susan E Wozniak; Kamran Khan; Sudhir K Dutta
Journal:  BMJ Case Rep       Date:  2016-01-20

Review 3.  Marijuana: current concepts(†).

Authors:  Donald E Greydanus; Elizabeth K Hawver; Megan M Greydanus; Joav Merrick
Journal:  Front Public Health       Date:  2013-10-10

4.  Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.

Authors:  Thangam Venkatesan; David J Levinthal; B U K Li; Sally E Tarbell; Kathleen A Adams; Robert M Issenman; Irene Sarosiek; Safwan S Jaradeh; Ravi N Sharaf; Shahnaz Sultan; Christopher D Stave; Andrew A Monte; William L Hasler
Journal:  Neurogastroenterol Motil       Date:  2019-06       Impact factor: 3.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.